One shot may shield HIV-Positive women from HPV

NCT ID NCT06436274

Ongoing Prevention Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single dose of the HPV vaccine (Gardasil 9) can prevent persistent HPV infection in women living with HIV who have already been vaccinated. About 778 women will receive either the HPV vaccine or a meningitis vaccine (placebo) and be monitored for safety and infection. The goal is to see if one dose is enough to protect this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HPV vaccine (Gardasil 9)
What this could lead to: If successful, a single HPV vaccine dose could protect women with HIV from persistent HPV infection, reducing cancer risk.
What could go wrong: This is a Phase 4 study, but results may not apply to all populations. The single-dose approach may be less effective than the standard series, and safety in this group is still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV HUMAN PAPILLOMA VIRUS

Contacts and locations

Locations

Botswana Harvard Health Partnership

Gaborone, 0000, Botswana
Ministry of Health and Center for Family Health Research

Kigali, Kigali, +250, Rwanda
Wits RHI, University of the Witwatersrand

Johannesburg, Gauteng, 2001, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.